Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Northwest Biotherapeutics Reports Encouraging Data on First Patients Who Have Completed Its Phase I/II Clinical Trial of DCVax(R)-L in Metastatic Ovarian Cancer
January 7th, 2009
(OTC Bulletin Board: NWBO; AIM: NWBT and NWBS) Northwest Biotherapeutics, Inc. ("NWBT") announced encouraging data on clinical responses in the first two case reports of patients who have completed the Company's Phase I/II clinical trial with DCVax(R)-L personalized cancer vaccine for recurrent, metastatic ovarian cancer. This trial is ongoing, and is treating "no option" patients who have already been treated with most or all major drugs currently available for recurrent, metastatic ovarian cancer (including carboplatin, paclitaxel, docetaxel, abraxane, gemcitabine and topotecan), and whose cancer has still continued to progress. In other recent clinical trials testing...
Source: Vaccine Weekly (2009-01-07)
|
